Reichert M, Atanasova S, Petri K, Kampschulte M, Kojonazarov B, Fuchs-Moll G
Int J Mol Sci. 2022; 23(15).
PMID: 35897686
PMC: 9331602.
DOI: 10.3390/ijms23158111.
Graves S, Mathes D, Storb R
OBM Transplant. 2020; 3(3).
PMID: 32944710
PMC: 7494220.
DOI: 10.21926/obm.transplant.1903080.
Ju L, Suberbielle C, Li X, Mooney N, Charron D
Front Med. 2018; 13(3):298-313.
PMID: 29974325
DOI: 10.1007/s11684-018-0636-x.
Hsiao H, Fernandez R, Tanaka S, Li W, Spahn J, Chiu S
J Clin Invest. 2018; 128(7):2833-2847.
PMID: 29781811
PMC: 6025976.
DOI: 10.1172/JCI98436.
Nayak D, Zhou F, Xu M, Huang J, Tsuji M, Yu J
Sci Transl Med. 2017; 9(398).
PMID: 28701473
PMC: 5846477.
DOI: 10.1126/scitranslmed.aal1243.
Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch.
Zou J, Duffy B, Slade M, Young A, Steward N, Hachem R
Hum Immunol. 2017; 78(4):342-349.
PMID: 28267558
PMC: 5595356.
DOI: 10.1016/j.humimm.2017.03.002.
De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II.
Xu Z, Nayak D, Benshoff N, Hachem R, Gelman A, Mohanakumar T
J Immunol. 2015; 194(12):6133-43.
PMID: 25941328
PMC: 4458403.
DOI: 10.4049/jimmunol.1401848.
Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.
Hlavaty K, Luo X, Shea L, Miller S
Clin Immunol. 2015; 160(1):14-23.
PMID: 25805659
PMC: 4554810.
DOI: 10.1016/j.clim.2015.03.013.
Cardiac allograft vasculopathy: a donor or recipient induced pathology?.
van den Hoogen P, Huibers M, Sluijter J, de Weger R
J Cardiovasc Transl Res. 2015; 8(2):106-16.
PMID: 25652948
PMC: 4382530.
DOI: 10.1007/s12265-015-9612-x.
Increased T cell glucose uptake reflects acute rejection in lung grafts.
Chen D, Wang X, Yamamoto S, Carpenter D, Engle J, Li W
Am J Transplant. 2013; 13(10):2540-9.
PMID: 23927673
PMC: 3956601.
DOI: 10.1111/ajt.12389.
Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.
Angaswamy N, Tiriveedhi V, Sarma N, Subramanian V, Klein C, Wellen J
Hum Immunol. 2013; 74(11):1478-85.
PMID: 23876679
PMC: 3813452.
DOI: 10.1016/j.humimm.2013.07.002.
Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies.
Basha H, Ramachandran S, Tiriveedhi V, Takenaka M, Subramanian V, Nath D
Transplantation. 2013; 95(2):293-300.
PMID: 23325004
PMC: 3549536.
DOI: 10.1097/TP.0b013e3182772244.
Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation.
Chernogorova P, Zeiser R
J Biomed Biotechnol. 2012; 2012:208204.
PMID: 23125523
PMC: 3482062.
DOI: 10.1155/2012/208204.
Antibodies to MHC class II molecules induce autoimmunity: critical role for macrophages in the immunopathogenesis of obliterative airway disease.
Takenaka M, Tiriveedhi V, Subramanian V, Hoshinaga K, Patterson A, Mohanakumar T
PLoS One. 2012; 7(8):e42370.
PMID: 22900015
PMC: 3416847.
DOI: 10.1371/journal.pone.0042370.
T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease.
Tiriveedhi V, Takenaka M, Ramachandran S, Gelman A, Subramanian V, Patterson G
Am J Transplant. 2012; 12(10):2663-74.
PMID: 22822907
PMC: 3459183.
DOI: 10.1111/j.1600-6143.2012.04191.x.
Role of antibodies to self-antigens in chronic allograft rejection: potential mechanism and therapeutic implications.
Sarma N, Tiriveedhi V, Angaswamy N, Mohanakumar T
Hum Immunol. 2012; 73(12):1275-81.
PMID: 22789626
PMC: 3496808.
DOI: 10.1016/j.humimm.2012.06.014.
An important role for autoimmunity in the immunopathogenesis of chronic allograft rejection.
Tiriveedhi V, Sarma N, Mohanakumar T
Int J Immunogenet. 2012; 39(5):373-80.
PMID: 22486939
PMC: 3396719.
DOI: 10.1111/j.1744-313X.2012.01112.x.
An obligatory role for lung infiltrating B cells in the immunopathogenesis of obliterative airway disease induced by antibodies to MHC class I molecules.
Fukami N, Ramachandran S, Takenaka M, Weber J, Subramanian V, Mohanakumar T
Am J Transplant. 2012; 12(4):867-76.
PMID: 22233464
PMC: 3721353.
DOI: 10.1111/j.1600-6143.2011.03917.x.
Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S, Dew M, Pilewski J, DeVito Dabbs A, Zaldonis D, Studer S
J Heart Lung Transplant. 2011; 30(7):743-54.
PMID: 21420318
PMC: 3110582.
DOI: 10.1016/j.healun.2011.01.714.
Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient.
Krumbholz A, Sandhaus T, Gohlert A, Heim A, Zell R, Egerer R
Med Microbiol Immunol. 2010; 199(4):317-22.
PMID: 20644957
DOI: 10.1007/s00430-010-0165-y.